CRISPR Therapeutics

2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group
Yahoo/Reuters
Vertex Pharmaceutials
CRISPR Therapeutics
gene therapy
sickle cell disease
ICER
Flag link:
Gene Editing Therapeutics Could Hit the Market in 2023
Gene Editing Therapeutics Could Hit the Market in 2023
BioSpace
gene editing
CRISPR Therapeutics
Vertex Pharmaceuticals
Intellia Therapeutics
Editas Medicine
Beam Therapeutics
Flag link:
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Yahoo/Businesswire
Vertex Pharmaceuticals
CRISPR Therapeutics
sickle cell disease
beta thalassemia
FDA
exa-cel
Flag link:
Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality
Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality
Endpoints
Vertex Pharmaceuticals
diabetes
CRISPR
gene editing
CRISPR Therapeutics
Flag link:
CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy
CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy
BioSpace
ViaCyte
CRISPR Therapeutics
Genprex
diabetes
gene therapy
Flag link:
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
BioPharma Dive
Medicaid
sickle cell disease
gene therapies
Bluebird Bio
Vertex Pharmaceuticals
CRISPR Therapeutics
Flag link:
EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval
EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval
Fierce Biotech
Vertex Pharmaceuticals
CRISPR Therapeutics
EMA
CRISPR
sickle cell disease
exa-cel
Flag link:
Two Aurinia execs are out — and CRISPR’s operations chief isn't far behind
Two Aurinia execs are out — and CRISPR’s operations chief isn't far behind
Endpoints
Aurinia Pharmaceuticals
CRISPR Therapeutics
Flag link:
The gloom deepens for biopharma stocks
The gloom deepens for biopharma stocks
EP Vantage
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Flag link:
Vertex given green light to seek US approval of CRISPR-based therapy
Vertex given green light to seek US approval of CRISPR-based therapy
BioPharma Dive
Vertex Pharmaceuticals
CRISPR
CRISPR Therapeutics
FDA
exa-cel
beta thalassemia
sickle cell disease
Flag link:
CRISPR Tx Drug Targeting CD70 Offers Early Hope for Difficult T Cell Lymphomas
CRISPR Tx Drug Targeting CD70 Offers Early Hope for Difficult T Cell Lymphomas
BioSpace
CRISPR Therapeutics
clinical trials
CTX130
CAR-T
solid tumors
T-cell lymphoma
Flag link:
CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise
CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise
BioSpace
CRISPR Therapeutics
CTX130
clinical trials
lymphoma
EHA
Flag link:
Record-breaking 2021 revenue shows there's more to Swiss biotech sector than Roche, Novartis
Record-breaking 2021 revenue shows there's more to Swiss biotech sector than Roche, Novartis
Fierce Biotech
biotech
Switzerland
Novartis
Roche
Sophia Genetics
CRISPR Therapeutics
Flag link:
Why CRISPR Therapeutics Stock Is Soaring Today
Why CRISPR Therapeutics Stock Is Soaring Today
Motley Fool
CRISPR Therapeutics
Flag link:
A big year for sickle cell
A big year for sickle cell
EP Vantage
sickle cell disease
Agios
mitapivat
CRISPR Therapeutics
CTX001
clinical trials
Flag link:
CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy that evades the immune system
CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy that evades the immune system
Endpoints
CRISPR Therapeutics
ViaCyte
Vertex Pharmaceuticals
type 1 diabetes
cell therapy
gene editing
Flag link:
CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T
CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T
BioPharma Dive
cancer
cell therapy
CRISPR Therapeutics
Flag link:
CRISPR Therapeutics takes a swing at ALS gene editing in discovery deal with AAV upstart Capsida
CRISPR Therapeutics takes a swing at ALS gene editing in discovery deal with AAV upstart Capsida
Endpoints
CRISPR Therapeutics
ALS
gene editing
Capsida
Flag link:
Vertex puts a blockbuster valuation on its CRISPR deal
Vertex puts a blockbuster valuation on its CRISPR deal
EP Vantage
Vertex Pharmaceuticals
CRISPR Therapeutics
CRISPR
gene editing
CTX001
M&A
Flag link:

Pages